Mechanisms of GIP in inhibiting cancer growth: Updates and perspectives
Authors:
- 14 June 2025
- journal article
- review article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 681, 125824
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Beijing Municipality (7222157)
- National Natural Science Foundation of China (82003809)
This publication has 104 references indexed in Scilit:
- MEK inhibitors and DA‐Raf, a dominant‐negative antagonist of the Ras–ERK pathway, prevent the migration and invasion of KRAS‐mutant cancer cellsCytoskeleton, 2024
- SKCa- and Kv1-type potassium channels and cancer: Promising therapeutic targets?Biochemical Pharmacology, 2023
- Mechanistic diversity involved in the desensitization of G protein-coupled receptorsArchives of Pharmacal Research, 2021
- The extracellular matrix in tumor progression and metastasisClinical & Experimental Metastasis, 2019
- Pharmacokinetic stability of macrocyclic peptide triazole HIV‐1 inactivators alone and in liposomesJournal of Peptide Science, 2019
- Alpha-fetoprotein: a renaissanceTumor Biology, 2013
- A Synthetic Peptide Derived from Alpha-fetoprotein Inhibits the Estradiol-induced Proliferation of Mammary Tumor Cells in Culture through the Modulation of p212008
- AFPep: an anti-breast cancer peptide that is orally activeBreast Cancer Research and Treatment, 2006
- Review of Growth Inhibitory Peptide as a Biotherapeutic agent for tumor growth, adhesion, and metastasisCancer and Metastasis Reviews, 2005
- Alpha-fetoprotein derived synthetic peptides: assay of an estrogen-modifying regulatory segmentMolecular and Cellular Endocrinology, 1996